In April 2026, Xunming Biotech, a company focused on the development of antibody drugs driven by intelligent agents, announced the completion of a US$35 million Series A+ financing round. This round was led by Sequoia Capital China, with participation from Matrix Partners China and Boyuan Capital, and continued support from existing investors including 5Y Capital, Qiming Venture Partners, and Niuli Capital. The funds will be used to advance the development of the company's proprietary innovative functional antibody design platform, AuraIDE™, enhance the capabilities of its foundational models and intelligent agents, improve high-throughput and high-content experimental platform facilities, and streamline key processes from project initiation, molecular design, and drug development to translational implementation, thereby accelerating the transition of diversified innovative drug pipelines to the clinical stage.